Effects of rt-PA intravenous thrombolysis on NIHSS score and adverse reactions in patients with acute ischemic stroke
Objective To investigate the effects of recombinant tissue-type plasminogen activator(rt-PA)intravenous thrombolysis on the National Institutes of Health Stroke Scale(NIHSS)score and adverse reactions in patients with acute ischemic stroke(AIS).Methods A total of 60 AIS patients admitted from January 2020 to March 2022 were selected as the research objects.According to the parity of admission number,the patients were randomly divided into control group and observation group,with 30 cases in each group.The control group was treated with atorvastatin calcium+urokinase,and the observation group was treated with rt-PA intravenous thrombolysis.The therapeutic effects of the two groups were compared.Results After treatment,the NIHSS score,hematocrit(HCT)and erythrocyte sedimentation rate(ESR)in the observation group were lower than those in the control group,and the level of superoxide dismutase(SOD)was higher than that in the control group,and the differences were statistically significant(P<0.05).At 3,7 and 14 d after administration,the level of S-100β protein in the observation group was lower than that in the control group,and the level of endothelin-1(ET-1)was higher than that in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion rt-PA intravenous thrombolysis in the treatment of AIS has an ideal effect.It can reduce the nerve and body function damage of patients and promote the recovery of nerve function,but it will increase the risk of bleeding.Clinical application should be cautious.
NETL
NSTL
万方数据
